ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The data highlights its RSV vaccine cuts hospitalizations in older adults
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Decision on EU marketing authorisation for this population expected by September 2024
Subscribe To Our Newsletter & Stay Updated
